Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01516983 : Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Histological or cytological confirmation of non-small cell lung cancer (NSCLC).

- Diagnosis of brain metastases on a Gadolinium-enhanced MRI. More than 3 sites of
intracranial metastases, or the longest diameter of the intracranial lesion is more
than 3cm.

- Positive EGFR mutation.

Exclusion Criteria:

- Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
erbitux.

- CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01516983      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740